Skip to main content

Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV.

Publication ,  Journal Article
Overton, ET; Kantor, A; Fitch, KV; Mosepele, M; Aberg, JA; Fichtenbaum, CJ; McComsey, GA; Malvestutto, C; Lu, MT; Negredo, E; Bernardino, J ...
Published in: AIDS
January 1, 2025

OBJECTIVES: To determine baseline prevalence of proteinuria and albuminuria among participants from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) and evaluate associated risk factors. DESIGN: Cross sectional analysis of a baseline sample of participants from the REPRIEVE Trial. METHODS: REPRIEVE is an international primary cardiovascular prevention randomized controlled trial (RCT) of pitavastatin calcium vs. placebo among people with HIV (PWH) on antiretroviral therapy (ART). A representative subset (2791 participants) had urine collected at study entry. Urine protein to creatinine ratios (uPCR) and albumin to creatinine ratios (uACR) were classified as normal, moderately increased and severely increased. These were dichotomized to Normal or Abnormal for log-binomial regression analysis. Demographic, cardiometabolic, and HIV-specific data were compared among those with normal versus abnormal results. RESULTS: Overall, median age 49 years, 41% female sex, 47% black or African American race, 36% had estimated glomerular filtration rate (eGFR) less than 90 ml/min/1.73 mm 2 . For uPCR, 27% had moderately or severely increased values. For uACR, 9% had moderately or severely increased values. In the fully adjusted model for proteinuria, female sex, older age, residence in sub-Saharan Africa or East Asia, lower BMI, lower CD4 + cell count, and use of tenofovir disoproxil fumarate (TDF) were associated with abnormal values. In the fully adjusted model for albuminuria, a diagnosis of hypertension (HTN) was associated with abnormal values. CONCLUSION: Abnormal proteinuria and albuminuria remain common (27 and 9%) despite controlled HIV. Lower current CD4 + count and TDF use were strongly associated with proteinuria. Certain modifiable comorbidities, including HTN and smoking, were associated with abnormal values. In PWH with preserved eGFR, urine measures identify subclinical kidney disease and afford the opportunity for intervention.

Duke Scholars

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

January 1, 2025

Volume

39

Issue

1

Start / End Page

31 / 39

Location

England

Related Subject Headings

  • Virology
  • Risk Factors
  • Proteinuria
  • Prevalence
  • Placebos
  • Middle Aged
  • Male
  • Humans
  • HIV Infections
  • Global Health
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Overton, E. T., Kantor, A., Fitch, K. V., Mosepele, M., Aberg, J. A., Fichtenbaum, C. J., … REPRIEVE Trial Investigators. (2025). Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV. AIDS, 39(1), 31–39. https://doi.org/10.1097/QAD.0000000000004016
Overton, Edgar T., Amy Kantor, Kathleen V. Fitch, Mosepele Mosepele, Judith A. Aberg, Carl J. Fichtenbaum, Grace A. McComsey, et al. “Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV.AIDS 39, no. 1 (January 1, 2025): 31–39. https://doi.org/10.1097/QAD.0000000000004016.
Overton ET, Kantor A, Fitch KV, Mosepele M, Aberg JA, Fichtenbaum CJ, et al. Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV. AIDS. 2025 Jan 1;39(1):31–9.
Overton, Edgar T., et al. “Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV.AIDS, vol. 39, no. 1, Jan. 2025, pp. 31–39. Pubmed, doi:10.1097/QAD.0000000000004016.
Overton ET, Kantor A, Fitch KV, Mosepele M, Aberg JA, Fichtenbaum CJ, McComsey GA, Malvestutto C, Lu MT, Negredo E, Bernardino J, Hickman AB, Douglas PS, Grinspoon SK, Zanni M, Ribaudo H, Wyatt C, REPRIEVE Trial Investigators. Proteinuria and albuminuria among a global primary cardiovascular disease prevention cohort of people with HIV. AIDS. 2025 Jan 1;39(1):31–39.

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

January 1, 2025

Volume

39

Issue

1

Start / End Page

31 / 39

Location

England

Related Subject Headings

  • Virology
  • Risk Factors
  • Proteinuria
  • Prevalence
  • Placebos
  • Middle Aged
  • Male
  • Humans
  • HIV Infections
  • Global Health